Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity

Anna Castleton,1 Aditi Dey,1 Brendan Beaton,1 Bella Patel,1 Anne Aucher,2 Daniel M. Davis,2,3 and Adele K. Fielding1

1Department of Hematology, University College London, London, United Kingdom; 2Department of Life Sciences, Imperial College London, London, United Kingdom; and 3Manchester Collaborative Center for Inflammation Research, University of Manchester, Manchester, United Kingdom

Key Points

- Human BM-MSCs can be used to successfully deliver systemic oncolytic measles virus virotherapy to ALL tumor targets.
- This approach permits circumvention of preexisting anti-mesenchymal immune immunity and enhanced therapeutic outcomes.

Clinical trials of oncolytic attenuated measles virus (MV) are ongoing, but successful systemic delivery in immune individuals remains a major challenge. We demonstrated high-titer anti-MV antibody in 16 adults with acute lymphoblastic leukemia (ALL) following treatments including numerous immunosuppressive drugs. To resolve this challenge, human bone marrow–derived mesenchymal stromal cells (BM-MSCs) were used to efficiently deliver MV in a systemic xenograft model of precursor B-lineage–ALL. BM-MSCs were successfully loaded with MV ex vivo, and MV was amplified intracellularly, without toxicity. Live cell confocal imaging demonstrated a viral hand-off between BM-MSCs and ALL targets in the presence of antibody. In a murine model of disseminated ALL, successful MV treatment (judged by bioluminescence quantification and survival) was completely abrogated by passive immunization with high-titer human anti-MV antibody. Importantly, no such abrogation was seen in immunized mice receiving MV delivered by BM-MSCs. These data support the use of BM-MSCs as cellular carriers for MV in patients with ALL. (Blood. 2014;123(9):1327-1335)

Introduction

Adult acute lymphoblastic leukemia (ALL) is an aggressive hematological malignancy with complete remission rates following initial induction therapy of 85% to 95%.1-8 Despite cycles of combined immunosuppressive and myelosuppressive chemotherapeutics, long-term survival is achieved in fewer than half of adults,9 and few patients with relapsed disease survive.10 The ability to quantify and monitor minimal residual disease in the majority of patients with ALL, provides a basis—already recognized by the regulatory authorities—for early intervention with novel therapeutics prior to overt disease relapse,11 which would be the optimal setting for novel biological therapies.

Oncolytic viruses (OVs) preferentially infect and lyse transformed cells, leaving normal cells relatively unharmed. They lack cross-resistance with existing therapies, and the acceptable safety profile of OVs has been demonstrated in numerous trials.12-16 Vaccine-strain live, attenuated MV (MV-Edm) has shown tumor-specific replication and antitumor activity in a range of malignancies,17-30 with published phase 1 clinical trials showing safety and some therapeutic promise in cutaneous T-cell lymphoma31 and ovarian cancer.32 Sophisticated manipulations of the vaccine MV genome can aid tumor targeting33-37 and assist with in vivo tracking.38-39 Despite this, the necessity to shield MV from neutralizing antibody during systemic delivery has not been appropriately addressed40-41 but is likely to preclude repeat dosing regimes and impact adversely on therapy.

There has been increasing interest in cell-based delivery systems to circumvent humoral immunity. Success of this strategy depends on efficient ex vivo cellular loading with virus, intracellular virus amplification, effective cellular targeting of tumor sites following systemic administration, and successful virus hand-off at the tumor site. A variety of primary leukocytes,42-44 immortalized cell lines,45 and progenitor cells46,47 have all undergone preclinical evaluation for this purpose, with varying degrees of therapeutic success. In reality, many of the potential candidates are technically difficult to isolate, culture, or expand ex vivo. Mesenchymal stromal cells (MSCs) are nonhematopoietic cells with the capacity to self-renew and differentiate into cell lineages of mesenchymal origin. They can be isolated from a number of different sources. In the present study, we used a murine model of disseminated ALL to investigate the ability of primary human bone marrow–derived MSCs (BM-MSCs) to act as cellular carriers, effectively delivering systemic measles virotherapy to mice passively immunized with high levels of human anti-MV antibodies.

Methods

Primary cells and cell lines

BM samples were obtained from consenting healthy volunteers undergoing BM harvest. Mononuclear cells, isolated by density gradient centrifugation

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

© 2014 by The American Society of Hematology
(Ficoll, Amersham Biosciences, Bucks, United Kingdom [UK]) were resuspended in MesenCult MSC media plus MesenCult stimulatory supplements (StemCell Technologies, Grenoble, France) and 1 ng/mL basic fibroblast growth factor (R&D Systems, Minneapolis, MN). Cells were plated at 1 \times 10^7/mL and nonadherent cells were removed after 1 to 2 days. Vero cells (CCL-81; ATCC) were maintained in Dulbecco’s modified Eagle medium ( Gibco/Invitrogen, Paisley, UK) supplemented with 5% heat-inactivated fetal bovine serum (Gibco/Invitrogen). Nalm-6 cells (ACC-128; DSMZ) were maintained in RPMI 1640 medium (Gibco/Invitrogen) supplemented with 10% fetal bovine serum. For in vivo precursor B-cell (B)-ALL xenograft models, we generated stably transduced Nalm-6-luc, using MoMLV vector encoding firefly luciferase (gift from Dr Martin Pule, United College London) and pCL-ampho packaging vector (Imgenex).

**BM-MSC characterization**

International Society for Cellular Therapy criteria were used to characterize BM-MSCs. Cells were assessed at passages 1 to 3 to confirm successful isolation and purity. Passages 3 to 7 BM-MSCs were used for experiments.

**Measles virus production and cellular infection**

Live, attenuated MV-NSe– or green fluorescent protein (GFP)-expressing counterpart was used for all experiments. MV was propagated on Vero cells at a multiplicity of infection (MOI) of 0.01 using standard techniques and titrated on Vero cells using the modified Kärber formula. For infection of BM-MSCs, cells were washed with phosphate-buffered saline (PBS), inoculated with virus in OptiMEM at the appropriate MOI, and incubated for 2 hours at 37°C before removing the virus and replacing with fresh medium. The time point after infection is taken from completion of the inoculation period. Fusion inhibitory peptide (FIP; Z-D-Phe-Phe-Gly-OH; Bachem; Switzerland) was added at 40 μg/mL.

**MV nucleocapsid mRNA quantification by real-time quantitative-polymerase chain reaction**

MV nucleocapsid (MV-N) mRNA was quantified by customized TaqMan gene expression real-time polymerase chain reaction (PCR) assay (Applied Biosystems). cDNA was mixed with 0.9 mM forward and reverse primers and a 0.25 mM TaqMan probe and labeled with FAM reporter dye. Triplicate reactions were run on an ABI 7500 (Applied Biosystems) with nontemplate controls in each plate. PCR cycle number at threshold is represented as Ct. Relative expression level of gene of interest was calculated using the 2^(-ΔΔCt) formula.

**MV-H glycoprotein immunostaining**

Cells were fixed at room temperature in 10% formalin, washed and incubated with anti-H antibody (Chemicon; 1:100 final dilution) or mouse IgG1 K (MOPC21; 1 μg/mL; Sigma-Aldrich), followed by polyclonal goat anti-mouse Biotin IgG (Sigma-Aldrich; 1:400), horseradish peroxidase streptavidin (Dako; 1:500), 3-amin-9-ethylcarbazole + High Sensitivity Substrate Chromogen (Dako), and counterstained using Carrazi’s hematoxylin.

**Viability assays**

For the 3-(4,5 dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay, BM-MSCs were plated in triplicate at 5 \times 10^4 cells/mL in round-bottomed 96-well plates and infected with MV-NSe for 24 hours. At appropriate time points, 20 μL of MTS reagent (CellTiter-96 AQueous MTS powder, reconstituted at 2 mg/mL; Promega) was added and read after incubation for 4 hours at 37°C (target absorption peak, 490 nm; reference, 650 nm) on a Tecan Sunrise absorbance reader (Jencons-PLS). Trypan blue viability dye was used to enumerate viable cells.

**Xenograft models**

CB17 severe combined immunodeficient (SCID) mice (Charles River Laboratories, Margate, UK) were housed in accordance with UK home office–approved protocol and used at 6 to 8 weeks old. For assessment of MV-infected BM-MSC localization to established ALL xenografts, 1 \times 10^6 viable Nalm-6 cells (in 200 μL PBS) were injected intravenously (IV). After 3 weeks, intra-BM (IBM) sampling was performed to confirm leukemia engraftment (supplemental Methods on the Blood Web site). Ten days later, animals received 1 \times 10^6 MV-luc–loaded BM-MSCs (or PBS control) IV. The fate of infected BM-MSCs was determined by bioluminescent imaging. Shaved animals were given 200 μL r-Luciferin (Caliper Life Sciences, Cheshire, UK) intraperitoneally (IP) and imaged under anesthetic using an IVIS 100 Lumina (Caliper Life Sciences, Cheshire, UK). Analysis was with Living Image 3.2 software. To assess therapeutic efficacy, disseminated ALL xenografts were established by IV injection of 1 \times 10^6 viable Nalm-6-luc cells (in 200 μL PBS). Weekly bioluminescent imaging was performed from week 3 onward. As treatment, 6 consecutive weekly IV injections of 1 \times 10^6 pfu MV-NSe, 1 \times 10^6 BM-MSCs preloaded with MV-NSe at an MOI of 1.0, or 1 \times 10^6 BM-MSCs alone were given, starting 3 days after tumor administration. Passively immunized mice received 50 IU anti-MV IgG IP, 3 hours before each MV injection. The primary end point was survival to humane end point, with the secondary end point being disease burden (assessed by bioluminescence imaging or by flow cytometric quantification).

**Live cell imaging**

BM-MSCs (5 \times 10^3) were infected with MV-NSe-GFP (MOI of 1) for 2 hours and cultured in 8-well chambered coverglasses (Chambered Borosilicate Coverglass; Laboratory-Tek). After 48 hours, 75 \times 10^3 Nalm-6 cells expressing red fluorescent protein (RFP) were added and directly imaged by resonance laser scanning confocal microscopy (TCS SP5 RS; Leica) using excitation wavelengths of 488 and 594 nm with 20× dry and 63× water immersion objectives (not applicable = 1.2) and analyzed by Velocity (National Institutes of Health).

**Enzyme-linked immunosorbent assay**

Measles virus IgG antibody was quantified in duplicate using a solid phase enzyme-linked immunosorbassay (IBI, International; RE57141). Optical density (OD) was measured at 450 nm (reference wavelength, 650 nm) using a Tecan Sunrise absorbance reader (Jencons-PLS). The concentration of samples was determined directly from the standard curve. Titers of 200 mIU/mL or higher were deemed MV immune.

**Statistical analysis**

Graphs were plotted using Prism 5.0 (GraphPad Software) and Microsoft Excel. Data are presented as mean, with error bars shown as standard error of the mean) where appropriate. Statistical analysis of survival curves was performed using the log-rank test. For all other analyses, unpaired Student t test or Mann-Whitney U test was used. P ≤ .05 was considered statistically significant.

**Results**

Anti-MV antibody titers remain high in adult ALL patients despite several months of intensive immunosuppressive therapy

The effect of immunosuppressive combination chemotherapy as delivered to adults with ALL on MV antibody titers is not known. We quantified anti-measles IgG antibody titers using an enzyme immunoassay in sera from 16 patients treated on the UK multicenter ALL trial UKALL14 (NCT01085617) both prior to and after up to 3 months of continuous therapy. Diagnostic sera were paired with samples taken at 1 of 2 time points following completion of a minimum of 8 weeks of chemotherapy including high-dose dexamethasone, vincristine, daunorubicin, 1-asparaginase, rituximab, 6-mercaptopurine, cytarabine, and cyclophosphamide. Surprisingly, anti-MV IgG antibody

From www.bloodjournal.org by guest on July 15, 2017. For personal use only.
BM-MSCs can be infected by oncolytic measles virus ex vivo and serve as effective virus producing units

MSCs were prepared from normal human BM, and their appropriate characteristics were demonstrated (supplemental Figure 1). To confirm the susceptibility of BM-MSCs to MV infection ex vivo, we evaluated cell surface expression of the known MV receptors CD46, CD150, and nectin 4 by flow cytometry. BM-MSCs consistently expressed vaccine strain receptor CD46, whereas the wild-type receptor CD150 and the epithelial receptor nectin 4 were not expressed (supplemental Figure 2). We then determined the optimum MOI and time point postinfection, at which maximal virus productivity occurs with minimum BM-MSC death. We infected BM-MSCs with MV-GFP at various MOIs and compared GFP expression daily postinfection. GFP positivity consistently showed a peak in intensity at 48 hours postinfection (hpi). Photomicrographs of representative experiments at 48 hpi with an MOI of 1.0 are shown in Figure 2Ai, demonstrating MV cytopathology, with widespread GFP-positive multinucleate syncytia. Cell surface MV-H glycoprotein expression correlated closely with GFP expression, reaching maximal intensity at 48 hpi (Figure 2Aii). The viability of BM-MSCs was formally assessed by MTS assay. Figure 2B shows relative cell proliferation at each time point for each MOI. At an MOI of 1.0, there was no significant difference in cell viability between time points. Subsequently, we determined viral genome by real-time quantitative-PCR quantification of MV-N mRNA (Figure 2Cii) and cell-associated and supernatant virus output by TCID50 (Figure 2Di-iii). No increment in MV-N mRNA was seen above an MOI of 1.0, and TCID50 data confirmed a peak in cell-associated virus productivity at 48 hpi. Notably, there was almost no virus shed into the supernatant. Finally, we demonstrated that on reducing virus-mediated cell-cell fusion and multinucleate syncytia formation by the postinfection addition of FIP to cell culture medium, cell-associated virus titers were higher at all time points postinfection (Figure 2Eii-iii), with a trend toward statistical significance at later time points. Trypan blue viability assay confirmed a reduction in MV-specific cell death for cells cultured with FIP compared with those cultured without (data not shown). Taken together, the data shown in Figure 2 confirm optimal conditions for ex vivo BM-MSC loading, using an MOI of 1.0 at a standard inoculation time of 2 hours and postinoculation culture in the presence of FIP. Harvest of loaded BM-MSCs was performed at 24 hpi to allow delivery at the optimal 48-hour productivity time point.

MV-loaded BM-MSCs localize to sites of ALL in the BM following intravenous infusion

To evaluate the ability of ex vivo loaded BM-MSCs to localize to established sites of ALL, we used a previously characterized model of disseminated precursor B-ALL.22 Six- to 8-week-old SCID mice were injected with $1 \times 10^6$ Nalm-6 cells IV. After 3 weeks, IBM sampling from the right femur confirmed tumor cell engraftment in all mice as demonstrated in representative flow cytometry plots (Figure 3A). Ten days later, to minimize the potentially confounding issue of BM-MSC homing toward injured tissues, passage 3 BM-MSCs were loaded ex vivo with MV-luc at an MOI of 1.0 and at 24 hpi, injected IV at $1 \times 10^6$ cells per mouse, with control mice receiving PBS alone. The fate of infected cells was tracked using daily bioluminescent imaging for 10 days. Representative images in Figure 3B confirm early localization of MV-infected BM-MSCs to lung parenchyma, consistent with first pass entrapment. Subsequently, the bioluminescence signal was relocalized to the ALL-containing BM, confirming the ability of MVLuc to reach distant tumor targets when delivered IV within BM-MSC. Furthermore, in 2 of 3 animals, bioluminescence colocalized to the opposite side to that used for IBM sampling, proving that homing is not solely related to injury from sampling method.

BM-MSCs allow successful virus delivery to tumor targets in the presence of humoral immunity

Next, we assessed the ability of BM-MSCs to deliver MV to ALL cells in the presence of preexisting neutralizing antibodies. Human anti-MV antisera were obtained from discard specimens. Anti-MV IgG was titrated in pooled, heat-inactivated sera using an enzyme immunoassay. MV-loaded BM-MSCs or naked MV was treated with serial dilutions of high titer anti-MV antibody serum ex vivo, before being overlaid onto the standard MV culture cell line, Vero. MV hand-off from BM-MSC to Vero was quantified by syncytia formation at 48 hours after overlay (Figure 4A). Naked MV was very effectively neutralized by anti-MV IgG—with syncytia being evident only at very low concentrations of antibody—1:256 or higher dilution. When Vero cells were overlaid with MV-infected BM-MSCs, significantly more syncytia were seen at all antibody concentrations. MV-infected BM-MSCs permitted MV hand-off, at high antibody concentrations (1:8 dilution), a 5-fold higher concentration...
than the minimum concentration (1:256 dilution) permissive to infection when naked MV is used. These data confirm the ability of BM-MSCs to protect MV against antibody neutralization in vitro. Using a dual color system, we performed live cell confocal microscopy to directly visualize virus hand-off between Nalm-6 ALL cells, stably transduced to express RFP and green MV-GFP-infected BM-MSCs. Representative images shown in Figure 4B demonstrate the different stages of a fusion event between a single red Nalm-6 cell and a large MV-GFP-infected BM-MSC syncytium, taking place over 20 minutes of coculture (representative live cell imaging in supplemental Video 1). The Nalm-6 cell is seen to transition from red, becoming yellow as heterofusion takes place, and subsequently green as MV-GFP hand-off occurs. Corresponding brightfield images are shown beneath each fluorescent image. We used the live cell imaging to probe the role of anti-MV antibodies in the BM-MSC-to-ALL cell contact time between cells rather than prevent fusion, BM-MSC-to-ALL cell contact time in the presence of 1:128 serum dilution was quantified for at least n = 125 events. The majority of heterofusion events were rapid, occurring within 20 minutes of coculture (Figure 4D) indicating that contact time between ALL and BM-MSC did not significantly change with the addition of anti-MV antibody. Taken together, the data in Figure 4 illustrate the ability of MV-infected BM-MSCs to readily hand off viable replicating MV to noninfected ALL cell targets, with BM-MSCs affording MV significant protection against neutralizing antibodies in vitro. A proportion of the virus hand-off occurs via the rapid process of carrier cell-to-tumor cell heterofusion.

BM-MSCs enhance the therapeutic efficacy of systemically delivered measles virotherapy in the presence of preexisting high titer anti-MV antibodies

We then determined whether the in vitro findings could be translated into therapeutic efficacy in an SCID murine model of precursor
B-ALL. Six- to 8-week-old SCID mice received IV injection with $1 \times 10^6$ Nalm-6 cells stably transduced to express firefly luciferase. On day 2, mice received IV injections of $1 \times 10^6$ plaque forming units (pfu) MV-NSe, $1 \times 10^6$ BM-MSCs loaded ex vivo (24 hours prior) with MV-NSe at an MOI of 1.0, or $1 \times 10^6$ uninfected BM-MSCs. Treatments continued weekly for a total of 6 weeks. Groups were further divided into mice receiving passive immunization with $50\,\text{IU}$ anti-measles IgG, delivered IP 3 hours before each therapy injection or those receiving PBS as a control. Tumor burden was quantified by bioluminescent imaging. OS was plotted using the method of Kaplan-Meier. Figure 5A shows the OS of all mice by treatment allocation. As expected, mice receiving only MSCs rapidly succumbed to ALL (median survival, 53 days), with significantly inferior outcome compared with either MV alone or MV-MSC alone ($P = .0001$ and $P = .0027$, respectively), clearly confirming the lack of therapeutic benefit of MSCs in this model. Naked MV enhanced survival, as expected. This effect is abrogated in the presence of anti-MV antibody (median survival, 64 days), with comparison of survival curves for naked MV treatment group vs naked MV [+ab] showing a statistically significant difference ($P = .0013$). Mice receiving MSC-delivered MV had the best antitumor responses (median survival > 100 days) with all animals surviving to the end of the experiment and significantly superior responses compared with standard naked MV treatment groups (MV [+ab] vs MV-MSC [+ab], $P = .0022$; MV alone vs MV-MSC alone, $P = .0234$). The administration of anti-MV antibody to mice receiving MV within MSCs did not abrogate the therapeutic effect at all. (Survival curve comparisons are reiterated in supplemental Table 1.) Figure 5B shows representative bioluminescent imaging performed at equivalent time points, pictorially representing the relative tumor burdens for animals in the different treatment groups. Figure 5C shows the week 6 tumor burden measurements, as assessed by bioluminescent activity for each animal, minus the background luminescence. The data in Figure 5A,C confirm a statistically significant therapeutic benefit of delivering MV within BM-MSCs in the presence of anti-MV humoral immunity. To ensure that any technical problems with ALL engraftment had not biased the results, flow cytometric evidence of ALL was sought at experiment termination in the BM of every animal in which bioluminescence did not show overt disease. All mice had some flow cytometric evidence of leukemia within the BM at termination (data not shown). These data confirm our previous finding that systemically administered MV can successfully treat mice with aggressive disseminated ALL. We showed that anti-MV antibody abrogates this therapeutic potential. However, administration of MV inside BM-MSC carriers protects the virus against antibody neutralization, allowing an ongoing therapeutic effect of systemically administered virus against disseminated tumor in the presence of high titer antibody.

**Discussion**

We have previously shown that disseminated precursor B-ALL xenografts in SCID mice are highly sensitive to MV-mediated oncolysis. For our planned phase 1 trial in patients with relapsed ALL, the coadministration of various immunosuppressive anti-ALL agents such as cyclophosphamide, steroid, or anti-B-cell monoclonal antibodies alongside MV therapy is under consideration, with the aim of suppressing an anti-MV response. This rationale is based on murine data suggesting that clinically approved cyclophosphamide regimens can suppress humoral anti-MV and anti-vesicular stomatitis virus responses. However, our data show, on sera samples taken from a subset of UKALL14 trial participants before and after intensive
immunosuppressive and myelosuppressive chemotherapy (including dexamethasone, anthracycline, vincristine, asparaginase, cyclophosphamide, and cytarabine), that clinically significant anti-MV antibodies persist in all cases, confirming the need for an alternative but clinically relevant strategy for circumvention.

We chose to investigate human BM-MSCs in our preclinical model for a number of reasons. First, MSCs are a highly clinically relevant commodity, with a wealth of data detailing the safe use of IV-delivered allogeneic or autologous BM-MSCs as a therapeutic strategy in several diseases including acute graft-versus-host disease following hematopoietic cell transplantation for hematological malignancy.53-55 Second, MSCs are hypoimmunogenic, permitting safe administration without preconditioning. Thus, allogeneic donor-mismatched BM-MSCs can potentially be an “off the shelf” commodity, allowing their use as virotherapeutic delivery vehicles but without themselves representing a target for elimination of the therapeutic element. Third, evidence suggests that MSCs colocate and interact with ALL in the BM microenvironment.56 Finally, based on preclinical studies investigating the migratory capacity of MSCs,57 we hypothesized that BM-MSCs would be likely to home to BM targets on systemic infusion. One recent murine study demonstrated that systemically administered BM-MSCs can deliver oncolytic MV to localized hepatocellular carcinoma tumor targets.58 However, the present study demonstrates for the first time the ability of BM-MSCs to enhance the efficacy of systemic measles virotherapy for a widely disseminated, BM-based malignancy such as ALL.

In addition to BM, MSCs can be isolated from a number of alternative sources, including adipose tissue.59 Subtle differences in their in vitro immunophenotype, differentiation capacity, and gene expression profile are seen compared with BM-MSCs, but the extent to which these features lead to biological differences in vivo remains unknown, and the MSC lineage needs to be carefully and rationally considered for each particular tumor type. Although adipose-derived MSCs have been used as IP delivery vehicles for oncolytic MV in a preclinical model of ovarian cancer,41 IV-administered BM-MSCs for the targeted delivery of an oncolytic virus to a BM-based malignancy is rapidly translatable, because it is fully compatible with current investigational and therapeutic approaches to ALL.

Our data show that in contrast to primary ALL tumor cells that typically die soon after viral infection,22 BM-MSCs—while readily infectable by MV—retain viability at 48 hpi and continue to produce...
virus. Furthermore, MV-loaded BM-MSCs localized to sites of ALL in the BM of mice following IV infusion. Before moving to therapeutic studies in mice, we were keen to precisely quantify the interaction between BM-MSCs and target ALL cells. The timescale over which virus hand-off occurs and whether this process occurs by fusion or by infection from released virus are important questions, as both parameters are likely to influence the potential success of this delivery approach in trials. Live cell confocal imaging confirmed that the majority of hand-off results from heterofusion and occurs rapidly—within 20 minutes of coculture—suggesting that virus delivery to tumor would take place in vivo long before BM-MSC viability is compromised and prior to any anamnestic response. Live cell confocal imaging was also used to visualize the impact of antiviral antibodies on this process. Heterofusion events—impossible unless MV-H and F glycoproteins are both displayed at the surface of the BM-MSCs—were predictably ablated in the presence of very high antibody concentrations and FIP, whereas at lower antibody concentrations, heterofusion events remained plentiful.
In vivo, passive immunization of animals prior to each MV administration was provided with injection of high titer anti-MV antiserum (50 IU anti-MV IgG), equating to an ultimate anti-MV antibody concentration several logs higher than the 300 mIU/mL deemed high titer in the clinical setting. This was quite sufficient to almost completely abrogate therapeutic responses to naked MV. However, successful delivery and therapeutic efficacy of BM-MSC–delivered oncolytic MV was demonstrated in this setting, suggesting successful MSC homing, virus hand-off, and ultimately therapeutic protection from repeated infusions of anti-MV antibody designed to model an anamnestic response. This is in contrast to the lack of abrogation of MV antitumor responses that we previously described when antiviral antibodies are delivered locally to MV-treated subcutaneous human B-cell lymphoma xenografts, further highlighting the central importance of shielding the virus from anti-MV antibodies during systemic delivery to a disseminated malignancy. Unexpectedly, delivering MV within BM-MSC carriers also improved anti-ALL efficacy beyond that seen with naked MV. Because BM-MSCs administered alone granted no survival benefit, we hypothesize that the continuing MV replication and production within the BM-MSCs enhances the virus payload reaching distant tumor targets.

Clinical validation is now required. An initial phase 1 trial of oncolytic MV in adult ALL is planned. Alongside efforts to determine the safety of IV-administered oncolytic MV in this disease, secondary goals will include the careful monitoring of humoral and cellular responses to injected virus to set a baseline for evaluation of immune shielding approaches. The strategy proposed here is compatible with rapid translation to the clinic and does not preclude an approach alongside immunosuppressive therapy.

Acknowledgments

This work was supported by a clinical training fellowship award to A.C. from Leukaemia and Lymphoma Research UK.

Authorship

Contribution: A.C. performed the research; A.C. and A.K.F. wrote the paper; A.D. provided technical assistance with animal work; B.B. performed the MV-IgG enzyme-linked immunosorbent assay on primary patient material; B.P. edited the manuscript; A.A. and D.M.D. performed the confocal imaging and confocal data analysis, and edited the manuscript; and A.K.F. supervised the study.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: A.K. Fielding, Department of Hematology, Royal Free Campus, University College London, Rowland Hill St, London NW3 2PF, UK; e-mail: a.fielding@ucl.ac.uk.

References


31. Heinzerling L, Künzi V, Oberholzer PA, Kündig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon- 


Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity

Anna Castleton, Aditi Dey, Brendan Beaton, Bella Patel, Anne Aucher, Daniel M. Davis and Adele K. Fielding